Newsfeeds - Spark Newswire

1 minute read

B. Riley Securities Downgrades Spectrum Pharmaceuticals to Neutral, Lowers Price Target to $1

Today, 11:48 AM

B. Riley Securities analyst Mayank Mamtani downgrades Spectrum Pharmaceuticals (NASDAQ:SPPI) from Buy to Neutral and lowers the price target from $1.5 to $1.

SPPI

1 minute read

Spectrum Pharmaceuticals Q3 EPS $(0.12) Beats $(0.15) Estimate

By Benzinga Newsdesk

Today, 11:48 AM

Spectrum Pharmaceuticals (NASDAQ:SPPI) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 25 percent increase over losses of $(0.16) per share

SPPI

6 minute read

Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 11:48 AM

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

APLS

30 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 11:48 AM

During Wednesday's trading, 517 companies set new 52-week lows.

$APE

47 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 11:48 AM

On Tuesday, 838 companies hit new 52-week lows.

$APE

4 minute read

AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 11:48 AM

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.

ALNY